PHOTO
Cairo, Egypt - Novo Nordisk, the leading global health care company, has appointed Dr. Ayman Hassan as the new Vice President and General Manager for the company’s operations in Egypt. With nearly 25 years of diverse experience in the medical field, the pharma industry, and business, Dr. Ayman Hassan has a wealth of expertise from his work across the Gulf, Middle East and South Asia.
"Novo Nordisk Egypt has achieved great success over 80 years operating in the Egyptian market. During those years Novo Nordisk has established meaningful partnerships with the Egyptian government, the medical societies, as well as patient organizations. We look forward to reaching new milestones in the company’s history in Egypt while further augmenting our position as a genuine partner of Egypt,” said Dr. Ayman Hassan, Vice President and General Manager, Novo Nordisk Egypt. “It is an honor and a privilege to take on this role as we continue our commitment to helping people with diabetes and other serious chronic conditions in Egypt and around the world."
Dr. Ayman Saad Hassan began his career with Novo Nordisk in 2000 when he joined Novo Nordisk Pharma Gulf based out of Riyadh as medico-marketing manager and eventually was promoted to director. He later assumed marketing responsibility for the Near East South Asia business area based out of Istanbul, where he helped establish and develop different sales, marketing and medical units and disciplines across countries spanning from Turkey to India. These endeavors covered a fourth of the world’s population. He then moved back to the Gulf to eventually establish a fully-fledged organization in the UAE.
Dr. Ayman Hassan graduated from the Faculty of Medicine, Cairo University. In addition to his medical degree, Dr. Hassan carries a Master’s Degree in Business Administration (MBA) from the USA, a Master of Science (M.Sc.) in Global Management from the UK, a Diploma in Clinical Trials from the UK, and an Executive Management Strategy Execution Certificate from Harvard University.
-Ends-
About Novo Nordisk:
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries.
For more information, visit: Novonordisk.com
For further information, please contact:
Mai Mohsen: 01025284447
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
